{
  "id": 6149904,
  "title": "Mumbai: FDA Suspends Kandivali Civic Hospital Blood Centre Licence For 3 Days Over Irregularities; Appeal Pending",
  "url": "https://urgent.news/2026/09/07/mumbai-fda-suspends-kandivali-civic-hospital-blood-centre-licence-for",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-07T16:28:19.000Z",
  "source": {
    "name": "Free Press Journal",
    "slug": "free-press-journal",
    "url": "https://www.freepressjournal.in/mumbai/mumbai-fda-suspends-kandivali-civic-hospital-blood-centre-licence-for-3-days-over-irregularities-appeal-pending"
  },
  "original_language": "en",
  "account": "Mumbai's Kandivali Civic Hospital blood centre faces a three-day suspension of its license due to irregularities, according to the Maharashtra Food and Drug Administration (FDA). The suspension was ordered after an inspection on March 2, 2026, with the FDA citing multiple issues, including unqualified personnel conducting haemoglobin tests, incomplete ledgers, and the blood centre operating only in one shift. The hospital administrator has filed an appeal, hoping the FDA will consider their case. The FDA also pointed out that the blood centre was staffed during a period when only one doctor was present, and the lead doctor had a skin disease, which violated applicable requirements. The action has raised concerns about how patients requiring blood transfusions during the closure will be cared for, especially those needing transfusions for surgeries, emergencies, or other critical treatments. The hospital has proposed alternative arrangements, stating that its own blood centre provides whole blood, and it has tie-ups with two other blood banks from where additional blood and components are accessible at rates decided by the BMC. Therefore, patients may still find blood and components through these linked blood banks while the suspension is enforced.",
  "summary": "Mumbai, September 7, 2026: Patients requiring blood transfusions at Bharatratna Babasaheb Ambedkar Municipal General Hospital in Kandivali West could face uncertainty in October, with the Maharashtra Food and Drug Administration (FDA) ordering a three-day suspension of the hospital’s blood centre licence over multiple irregularities. The FDA issued the suspension letter on July 27, 2026,…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}